JP2024535432A5 - - Google Patents
Info
- Publication number
- JP2024535432A5 JP2024535432A5 JP2024519062A JP2024519062A JP2024535432A5 JP 2024535432 A5 JP2024535432 A5 JP 2024535432A5 JP 2024519062 A JP2024519062 A JP 2024519062A JP 2024519062 A JP2024519062 A JP 2024519062A JP 2024535432 A5 JP2024535432 A5 JP 2024535432A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- pcdh19
- mutation
- oligonucleotide according
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248803P | 2021-09-27 | 2021-09-27 | |
| US63/248,803 | 2021-09-27 | ||
| US202263333840P | 2022-04-22 | 2022-04-22 | |
| US63/333,840 | 2022-04-22 | ||
| PCT/AU2022/051153 WO2023044545A1 (en) | 2021-09-27 | 2022-09-27 | Compositions and methods for the treatment of pcdh19 related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535432A JP2024535432A (ja) | 2024-09-30 |
| JP2024535432A5 true JP2024535432A5 (https=) | 2025-10-29 |
Family
ID=85719092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519062A Pending JP2024535432A (ja) | 2021-09-27 | 2022-09-27 | Ｐｃｄｈ１９関連障害の治療のための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250002912A1 (https=) |
| EP (1) | EP4408532A4 (https=) |
| JP (1) | JP2024535432A (https=) |
| KR (1) | KR20240068067A (https=) |
| AU (1) | AU2022351990A1 (https=) |
| CA (1) | CA3232862A1 (https=) |
| CL (1) | CL2024000853A1 (https=) |
| CO (1) | CO2024004737A2 (https=) |
| IL (1) | IL311581A (https=) |
| MX (1) | MX2024003947A (https=) |
| PE (1) | PE20250738A1 (https=) |
| WO (1) | WO2023044545A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024206668A1 (en) * | 2023-03-31 | 2024-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic strategy for pcdh19-related encephalopathy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5624892B2 (ja) * | 2008-01-04 | 2014-11-12 | セントラル アデレード ローカル ヘルス ネットワーク インコーポレイテッド | Ｅｆｍｒ（女性に限られた癲癇及び精神遅滞）の診断方法及び治療方法 |
| EP3118326B1 (en) * | 2008-10-27 | 2020-04-29 | Sapporo Medical University | Molecular marker for cancer stem cell |
| US9562892B2 (en) * | 2012-10-02 | 2017-02-07 | New York University | Methods and agents for modulating protocadherin-18 activity |
| WO2020191233A1 (en) * | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
-
2022
- 2022-09-27 EP EP22871200.6A patent/EP4408532A4/en active Pending
- 2022-09-27 KR KR1020247014017A patent/KR20240068067A/ko active Pending
- 2022-09-27 US US18/694,295 patent/US20250002912A1/en active Pending
- 2022-09-27 IL IL311581A patent/IL311581A/en unknown
- 2022-09-27 CA CA3232862A patent/CA3232862A1/en active Pending
- 2022-09-27 AU AU2022351990A patent/AU2022351990A1/en active Pending
- 2022-09-27 PE PE2024000576A patent/PE20250738A1/es unknown
- 2022-09-27 JP JP2024519062A patent/JP2024535432A/ja active Pending
- 2022-09-27 MX MX2024003947A patent/MX2024003947A/es unknown
- 2022-09-27 WO PCT/AU2022/051153 patent/WO2023044545A1/en not_active Ceased
-
2024
- 2024-03-22 CL CL2024000853A patent/CL2024000853A1/es unknown
- 2024-04-16 CO CONC2024/0004737A patent/CO2024004737A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6865871B2 (ja) | 酸性α−グルコシダーゼにおけるアンチセンス誘導エクソン２包含 | |
| JP7554488B2 (ja) | 血液脳関門通過型ヘテロ２本鎖核酸 | |
| US20220307019A1 (en) | Double-stranded nucleic acid complex and use thereof | |
| US20220127612A1 (en) | Methods and compositions for modulating splicing and translation | |
| EP2978845B1 (en) | Modified tgf-beta oligonucleotides | |
| AU2022202991A1 (en) | Organic compositions to treat KRAS-related diseases | |
| JP2022188194A (ja) | Ａｔｘｎ３を標的とするアンチセンスオリゴヌクレオチド | |
| JP2017516461A (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| TWI902655B (zh) | 單股寡核苷酸 | |
| EP3122365B1 (en) | Transthyretin allele selective una oligomers for gene silencing | |
| JP2022515744A5 (https=) | ||
| WO2019181946A1 (ja) | 毒性が軽減した核酸 | |
| JP2022522205A (ja) | 病態及び疾患の治療用アンチセンスオリゴマー | |
| WO2021153747A1 (ja) | Ａｔｎ１のアンチセンスオリゴヌクレオチド | |
| JP2024535432A5 (https=) | ||
| TW202102676A (zh) | 調節atxn2表現之寡核苷酸 | |
| JP2024522147A5 (https=) | ||
| CN116096420A (zh) | 利用miR-33b抑制物质的动脉瘤的预防或治疗 | |
| JPWO2020171149A1 (ja) | ヘテロ核酸の最適ｐｓ修飾パターン | |
| AU2022393586A1 (en) | Methods of treating headaches and migraines with sodium voltage-gated channel alpha subunit 11 (scn11a) inhibitors | |
| CN115698290A (zh) | 用于治疗神经系统疾病的补体组分4抑制剂以及使用它们的相关组合物、系统和方法 | |
| WO2024077262A2 (en) | Methods and compositions for silencing elavl2 expression for the treatment of disease | |
| US20250388902A1 (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
| WO2025096087A1 (en) | Treatment of myeloid cell dysfunction with membrane spanning 4-domains a6a (ms4a6a) inhibitors | |
| KR20260026011A (ko) | 타우 발현을 조절하기 위한 조성물 및 방법 |